[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
June 22 2011

Direct-to-Consumer Cardiac Screening and Suspect Risk Evaluation

Author Affiliations

Author Affiliations: Kaiser Permanente, San Diego, California (Dr Lovett); Department of Family and Preventive Medicine (Dr Lovett), and Anesthesiology, and San Diego Center for Patient Safety (Dr Liang) UCSD School of Medicine; and Institute of Health Law Studies, California Western School of Law (Dr Liang), San Diego.

JAMA. 2011;305(24):2567-2568. doi:10.1001/jama.2011.865

Direct-to-consumer (DTC) genetic testing has generated much concern due to nonstandardized products, unproven utility, and potential harm from testing results.1 Recommendations indicate that genetic testing should be US Food and Drug Administration (FDA)–approved, supported by predictive value and outcomes research, and offered only through qualified health care professionals.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×